Skip to main content
About Croma – Press & Downloads – Croma-Pharma receives marketing authorisation for Letybo® in a further 12 European markets
Halbe Breite 1000x667 LETYBO v24

Croma-Pharma receives marketing authorisation for Letybo® in a further 12 European markets

Croma announced today that it has received marketing authorisation for Letybo®, the company’s botulinum toxin product, in 12 additional European markets. These include Belgium, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Luxembourg, Malta, Norway, Slovakia and Sweden. Letybo® will be launched in these countries in the coming weeks.

Downloads

Croma-Pharma receives marketing authorisation for Letybo ® in a further 12 European markets (101 KB)
Back to top

If you are a healthcare professional (HCP), please log in to see specific information about our products.

Login

I've lost my password

Registration

* fields are required

This website uses cookies

We use cookies to personalise content, to provide social media features and to analyse our traffic. We also share information about your use of our website with our social media and analytics partners, which they may combine with other information you have provided to them or that they have collected from your use of their services. You consent to our cookies if you continue to use our website.